StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Keros Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $75.86M, down 59.4% year over year. For fiscal 2025 it was $129.64M, down 25.3% from the year before. The highest annual figure on record is $173.63M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$129.64M-25.3%
FY2024Dec 31, 2024$173.63M+28.4%
FY2023Dec 31, 2023$135.26M+55.0%
FY2022Dec 31, 2022$87.27M+58.3%
FY2021Dec 31, 2021$55.14M+62.9%
FY2020Dec 31, 2020$33.86M+94.8%
FY2019Dec 31, 2019$17.38M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.33M-48.7%
Q1 FY2026Mar 31, 2026$16.10M-67.0%
Q4 FY2025Dec 31, 2025$17.91M-60.7%
Q3 FY2025Sep 30, 2025$19.52M-60.3%
Q2 FY2025Jun 30, 2025$43.50M+7.4%
Q1 FY2025Mar 31, 2025$48.71M+27.3%
Q4 FY2024Dec 31, 2024$45.63M+21.7%
Q3 FY2024Sep 30, 2024$49.23M+44.2%
Q2 FY2024Jun 30, 2024$40.52M+24.5%
Q1 FY2024Mar 31, 2024$38.26M+23.1%
Q4 FY2023Dec 31, 2023$37.49M+50.8%
Q3 FY2023Sep 30, 2023$34.14M+62.3%
Q2 FY2023Jun 30, 2023$32.53M+39.7%
Q1 FY2023Mar 31, 2023$31.09M+72.0%
Q4 FY2022Dec 31, 2022$24.87M+32.0%
Q3 FY2022Sep 30, 2022$21.04M+41.8%
Q2 FY2022Jun 30, 2022$23.28M+133.2%
Q1 FY2022Mar 31, 2022$18.08M+57.3%
Q4 FY2021Dec 31, 2021$18.83M+94.7%
Q3 FY2021Sep 30, 2021$14.83M+76.7%
Q2 FY2021Jun 30, 2021$9.98M+37.4%
Q1 FY2021Mar 31, 2021$11.50M+34.8%
Q4 FY2020Dec 31, 2020$9.67M+132.5%
Q3 FY2020Sep 30, 2020$8.40M+117.8%
Q2 FY2020Jun 30, 2020$7.26M+61.5%
Q1 FY2020Mar 31, 2020$8.53M+75.2%
Q4 FY2019Dec 31, 2019$4.16M–
Q3 FY2019Sep 30, 2019$3.85M–
Q2 FY2019Jun 30, 2019$4.50M–
Q1 FY2019Mar 31, 2019$4.87M–

More Keros Therapeutics figures

See a number that looks wrong?